Subscribe to access the full database, or Start Trial
Tradename	Generic Name
ACETAMINOPHEN AND IBUPROFEN	acetaminophen; ibuprofen
ADVIL DUAL ACTION WITH ACETAMINOPHEN	acetaminophen; ibuprofen
COMBOGESIC	acetaminophen; ibuprofen
COMBOGESIC IV	acetaminophen; ibuprofen sodium
>Tradename	>Generic Name

Last updated: February 20, 2026

What Are Propionic Acid Derivatives, and How Are They Used?

Propionic acid derivatives in ATC class M01AE include drugs that feature a propionic acid backbone. They possess anti-inflammatory and analgesic properties, primarily used in musculoskeletal conditions and osteoarthritis management. Common examples include ibuprofen, naproxen, and other non-steroidal anti-inflammatory drugs (NSAIDs).

What Is the Current Market Size and Growth Trajectory?

The global NSAID market, dominated by propionic acid derivatives, was valued at approximately USD 12.7 billion in 2022. It is projected to grow at a compound annual growth rate (CAGR) of 4.3% from 2023 to 2028. This growth stems from increasing prevalence of chronic pain, osteoarthritis, and rheumatoid arthritis, especially in aging populations.

Key Market Segments:

Over-the-counter (OTC): 65% revenue share
Prescription NSAIDs: 35% revenue share
Geographic split:
- North America: 38%
- Europe: 27%
- Asia-Pacific: 20%
- Rest of world: 15%

What Are Major Market Drivers and Challenges?

Drivers:

Aging populations increasing demand for pain management solutions.
Rising prevalence of musculoskeletal disorders.
Generic drug availability reducing prices, expanding access.
Growing awareness of NSAID safety profiles leading to broader use.

Challenges:

Safety concerns regarding gastrointestinal and cardiovascular side effects.
Regulatory restrictions due to adverse event reports.
Competition from alternative analgesics and new NSAID formulations, such as topical preparations and selective COX-2 inhibitors.
Patent expiries on major drugs, leading to increased generic competition.

How Does the Patent Landscape Look?

Patent protection for propionic acid derivatives has largely expired, particularly for blockbuster drugs like ibuprofen and naproxen, which were introduced in the 1960s through the 1990s.

Key Patent Expiry Timeline:

Drug	Original Patent Filing Year	Patent Expiry Year	Notable Follow-up Patents
Ibuprofen	1960	1996	Formulation patents (e.g., extended-release) till 2010
Naproxen	1970	1990	New salt forms and formulations till 2005

Patent Trends:

Most original compound patents expired by 2000.
Fragmentation of patent rights via formulation, method of use, and delivery system patents until approximately 2015.
Recent patent filings focus on novel formulations, delivery methods, and combination drugs to extend market exclusivity.

Emerging Patent Strategies:

Development of topical NSAID formulations to target localized pain.
Combination therapies with other analgesics or anti-inflammatory agents.
Liposomal and nanoparticle delivery systems aimed at improving bioavailability and safety.

What Is the Competitive Landscape?

The market is characterized by a dominance of generic manufacturers due to patent expiries. Key players include:

Bayer AG (Nurada)
Johnson & Johnson (Motrin)
Boehringer Ingelheim (Nurofen)
Novartis (Anaprox)

Innovation is limited but focus remains on improving drug safety, tolerability, and delivery. Pharmaceutical startups explore novel formulations, though with limited market reach so far.

Regulatory Environment

The European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) regulate NSAIDs.
Safety concerns have led to revised dosing guidelines and boxed warnings.
Approval pathways for new formulations or combination drugs follow standard regulatory procedures, emphasizing demonstration of improved safety or efficacy.

Conclusions

The propionic acid derivatives segment faces a mature landscape with significant patent expiries. Growth hinges on safety improvements, novel formulations, and expanded indications. The market consolidates around generics, with limited innovation in core molecules but sustained interest in delivery system innovations.

Key Takeaways

The NSAID segment, dominated by propionic acid derivatives, remains sizable, projected to grow around 4.3% CAGR through 2028.
Major patents have expired, leading to high generic competition.
Innovation focuses on new formulations, delivery methods, and safety profiles.
Regulatory pressures and safety concerns shape market dynamics.
The competitive landscape is segmented between legacy pharma companies and emerging startups exploring novel formulations.

FAQs

1. What factors are driving growth in the propionic acid derivatives market?
The rise in chronic pain conditions in aging populations and increased NSAID prescriptions in emerging markets drive growth. Price reductions due to patent expiries and expanding OTC availability also boost demand.

2. When did key patents for ibuprofen and naproxen expire?
Ibuprofen patents expired in 1996, while naproxen patents expired in 1990. Follow-up formulations continued patent protection until around 2010–2015.

3. Are there ongoing patent filings for new NSAID formulations?
Yes; recent patents focus on topical formulations, combination therapies, and novel delivery systems aimed at reducing side effects.

4. Who are the main competitors in the NSAID space targeting propionic acid derivatives?
Major pharmaceutical companies include Bayer, Johnson & Johnson, Boehringer Ingelheim, and Novartis. Many companies focus on generics and minor formulation enhancements.

5. What regulatory challenges exist for new NSAID formulations?
Regulatory agencies require evidence of safety and efficacy, especially given the cardiovascular and gastrointestinal risks associated with NSAIDs. Reduced tolerability prompts stricter approval standards for new formulations.

References

[1] Research and Markets. (2022). "NSAID Market Size, Trends & Forecasts."
[2] U.S. Food and Drug Administration (FDA). (2023). "Nonsteroidal Anti-Inflammatory Drugs (NSAIDs) – Drug Safety Communications."
[3] European Medicines Agency (EMA). (2023). "Guidelines on the development of NSAID formulations."
[4] Grand View Research. (2022). "Propionic Acid Derivatives Market Analysis."

Drugs in ATC Class M01AE

Drugs in ATC Class: M01AE - Propionic acid derivatives

Market Dynamics and Patent Landscape for ATC Class M01AE – Propionic Acid Derivatives